Search Results 421-430 of 17118 for nivolumab

1. Oncology (Medical) - Clinical trials

   In-home Versus In-Clinic Subcutaneous Nivolumab Administration Through Connected And Remote Cancer CARE Beyond Walls. Jacksonville, Fla. The purpose of this ...

2. A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors - Mayo Clinic

   Has a known hypersensitivity to TSR-022, TSR-042, TSR-033 or to nivolumab (if applicable) components or excipients. Participating Mayo Clinic locations.

3. Fallopian Tube Cancer Clinical Trials - Mayo Clinic Research

   ... Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors Jacksonville, FL ... The purpose of this study is to characterize the safety and ...

4. Publications - Ben George, M.B.B.S., M.D. - Mayo Clinic

   ... Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 Jan 1; 115 (1):202-213 ...

5. Urology - Clinical trials

   This study hopes to determine the levels of bladder cancer-derived extracellular vesicles pre- and post-RC. In-home Versus In-Clinic Subcutaneous Nivolumab ...

6. Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer - Mayo Clinic

   ... nivolumab, as well as PD-L1 targeted antibodies such as durvalumab; these agents may have been administered as part of a clinical trial; Cohort 2 (colorectal ...

7. Building a Healthy Body after Cancer: Challenges and Opportunities in Healthy Exercise after Treatment for Young Adult Lymphoma Survivors - Mayo Clinic

   6 months to 5 years post-treatment, as well as those in disease remission who are being treated with immunotherapies like Nivolumab. Exclusion Criteria ...

8. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   Lack of response to therapy with a PD-1- or PD-L1-targeting monoclonal antibody (pembrolizumab, nivolumab, etc.) after at least 18 weeks of therapy OR ...

9. Gastroenterology and Hepatology - Clinical trials

   In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls. Jacksonville, Fla. The purpose of this ...

10. Where we are with gastric and esophageal cancers - Mayo Clinic

    Similarly, the U.S. FDA approved the combination of chemotherapy with another checkpoint inhibitor, nivolumab, in metastatic gastric adenocarcinoma. The ...